Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Pramlintide

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

AstraZeneca · Phase 2 · Completed · Enrollment 636

NCT00673387

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebo-P + Placebo-Mn/rn/rn/rn/r
Pramlintide 360 mcg + Placebo-Mn/rn/rn/rn/r
Placebo-P + Metreleptin 5.0 mgn/rn/rn/rn/r
Pramlintide 180 mcg + Metreleptin 2.5 mgn/rn/rn/rn/r
Pramlintide 180 mcg + Metreleptin 5.0 mgn/rn/rn/rn/r
Pramlintide 360 mcg + Metreleptin 1.25 mgn/rn/rn/rn/r
Pramlintide 360 mcg + Metreleptin 2.5 mgn/rn/rn/rn/r
Pramlintide 360 mcg + Metreleptin 5.0 mgn/rn/rn/rn/r

Not shown

  • Placebo-P + Placebo-M: endpoint not reported
  • Pramlintide 360 mcg + Placebo-M: endpoint not reported
  • Placebo-P + Metreleptin 5.0 mg: endpoint not reported
  • Pramlintide 180 mcg + Metreleptin 2.5 mg: endpoint not reported
  • Pramlintide 180 mcg + Metreleptin 5.0 mg: endpoint not reported
  • Pramlintide 360 mcg + Metreleptin 1.25 mg: endpoint not reported
  • Pramlintide 360 mcg + Metreleptin 2.5 mg: endpoint not reported
  • Pramlintide 360 mcg + Metreleptin 5.0 mg: endpoint not reported